BERLIN (Reuters) – Business software group SAP has been selected by Moderna (NASDAQ:) to help distribute the potential COVID-19 vaccine that the U.S. pharmaceuticals company is developing, CEO Christian Klein said on Monday.
“Moderna just selected SAP to help with distribution of the potential vaccine it is developing,” Klein told analysts on a conference call, discussing the development of SAP’s logistics and supply-chain business.
Moderna Inc said earlier it has started a U.S. government-backed late-stage trial for its vaccine candidate, the first to be implemented under the Trump administration’s Operation Warp Speed anti-coronavirus programme.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.